For more than four years, immunotherapy has been available as a first-line treatment for patients with Advanced and Metastatic Esophageal Cancer who are not eligible for surgery.

In 2021, patients who are candidates for surgery also became eligible to receive immunotherapy – but only after their esophagectomies.

Now, a significant body of research supports the incorporation of immunotherapy into treatment before surgery for patients who are eligible for esophagectomy.

Join us for a free webinar that examines that exciting development in the treatment of Esophageal Cancer

All registrants will receive a recording of the session.